Successful Termination of Insulin Therapy in Transient Neonatal Diabetes Mellitus

Published On: 18 Apr, 2024 1:44 PM | Updated On: 18 Apr, 2024 3:59 PM

Successful Termination of Insulin Therapy in Transient Neonatal Diabetes Mellitus

A report describes a case of a 29-day-old baby boy with fetal growth restriction and born by induction at 40 weeks. He was small for his gestational age and showed hyperglycemia of 413 mg/dL at four days of age. Blood analysis revealed glucose at 377 mg/dL and insulin at 1.0 μU/mL, prompting a diagnosis of Neonatal Diabetes Mellitus (NDM). 


He received a continuous intravenous insulin infusion, and his C-peptide was recorded as 0.08 ng/mL within 15 days.


At 29 days of age, the patient showed macroglossia and an umbilical hernia, thus directing 6q24-related diabetes mellitus. He received SAP therapy on the 39th day of life. The patient weighed 3,355 g on the first day of SAP therapy and received 0.075 U/h insulin dose for the following reasons: (i) High blood glucose levels for several days and (ii) Slower onset of insulin activity when administered subcutaneously. 


The patient showed improvement in blood glucose level, lowering from 170 mg/dL to 70 mg/dL in 2 h. His dose was then reduced to 0.05 U/h, resulting in no hypoglycemia and improved blood glucose control.  


The baby received a discharge at 58 days of age, with no hyperglycemia reported after that. Genetic analysis confirmed hypomethylation within 6q24 on one of the alleles, backing the diagnosis of 6q24-related diabetes mellitus.


Sakai R, Kikuchi N, Nishi D, et al. Successful Termination of Insulin Therapy in Transient Neonatal Diabetes Mellitus. Case Reports in Pediatrics. 2023;2023. https://doi.org/10.1155/2023/6667330

user
IJCP Editorial Team

Comprising seasoned professionals and experts from the medical field, the IJCP editorial team is dedicated to delivering timely and accurate content and thriving to provide attention-grabbing information for the readers. What sets them apart are their diverse expertise, spanning academia, research, and clinical practice, and their dedication to upholding the highest standards of quality and integrity. With a wealth of experience and a commitment to excellence, the IJCP editorial team strives to provide valuable perspectives, the latest trends, and in-depth analyses across various medical domains, all in a way that keeps you interested and engaged.

 More FAQs by IJCP Editorial Team
Logo

Medtalks is India's fastest growing Healthcare Learning and Patient Education Platform designed and developed to help doctors and other medical professionals to cater educational and training needs and to discover, discuss and learn the latest and best practices across 100+ medical specialties. Also find India Healthcare Latest Health News & Updates on the India Healthcare at Medtalks